Review Article
CRASH-2 Study of Tranexamic Acid to Treat Bleeding in Trauma Patients: A Controversy Fueled by Science and Social Media
Table 1
Randomized controlled trials involving TXA use.
| Study | Author(s) | Description | Year | Outcomes | Recommendations |
| CRASH-2 [1] | Shakur et al. | 20,211 pts with recruitment by “uncertainty principle” | 2010 | All-cause mortality 14.5% tranexamic acid (TXA) group versus 16.0% placebo group, ; vascular occlusion 0.3% TXA group versus 0.5% placebo group, | Tranexamic acid should be used in bleeding trauma patients |
| PATCH [10] | Gruen et al. | 1184 pts in shock determined by COAST criteria | July 2014 start date | Ongoing study | |
| STAAMP [11] | Universities of Pittsburgh, Rochester, Texas at San Antonio, and Utah | 1000 pts with prehospital shock and nonshock | July 2015 start date | Ongoing study | |
| TAMPITI [12] | Spinella and Bochicchio | 150 pts who received one blood product and/or immediate transfer to OR | Fall 2015–Spring 2017 | Ongoing study | |
| Tranexamic Acid in Orthopaedic Trauma Surgery [13] | Kiner | 100 pts with orthopaedic trauma (hip or knee) | May 2012–Dec. 2015 | Ongoing study | |
|
|